関連レポート

次世代がん診断：技術および世界市場2027年予測

出版元：Transparency Market Research  出版元について

発行年：2023年12月

定価：Single User License $5795 Multi User License $8795 Corporate User License $11795

ご請求は円換算（お見積り日TTSレート）となります。

ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。

納品形態：PDF by Email

当調査レポートは英文 226ページになります。

商品コード：TMR171

当レポートは発行年月に関わらず、受注の都度、最新情報にアップデートしてお届けいたします。ご希望情報の追加等もご相談可能です。

レポート紹介

抗がん剤の世界市場規模は2022年で1402億ドル、2031年に3031億ドル、市場の平均年成長率は9.1%に拡大していく予想です。

当レポートでは、抗がん剤の市場予測-2031年、各種セグメント別市場分析(薬剤タイプ別、治療タイプ別、国地域別、等)、COVID-19の影響、SWOT分析、主要企業プロフィールなどの情報を盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】
■抗がん剤の世界市場予測2023-2031年
・市場規模(US$)

■薬剤タイプ別、市場-2031年
細胞毒性薬
・アルキル化剤
・代謝拮抗薬
・その他

標的薬
・モノクローナル抗体
・チロシンキナーゼ阻害剤
・その他

ホルモン剤
※(市場規模US$)

■治療タイプ別、市場-2031年
化学療法
標的療法
免疫療法
その他
※(市場規模US$)

■がんタイプ別、市場-2031年
肺がん
乳がん
白血病
大腸がん
その他
※(市場規模US$)

■主要国地域別市場-2031年
北米
・米国、カナダ
欧州
・英国、ドイツ、英国、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・オーストラリア/ニュージーランド
・その他アジア太平洋
中南米
・ブラジル、メキシコ
・その他中南米
中東アフリカ
・GCC諸国、南アフリカ
・その他中東アフリカ
※地域別に各種セグメント別の細分化データ掲載、詳細は目次参照

■市場分析
市場ダイナミクス（促進要因、障壁、機会）
パイプライン分析
COVID-19の影響
競合状況
市場シェア分析
SWOT分析

■抗がん剤の主要企業プロフィール動向
Amgen Inc.
武田薬品工業株式会社
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Novartis AG
Pfizer Inc.
Bayer AG
Merck & Co. Inc.
Celgene Corporation
（全226頁）

Table of Contents (英文詳細目次）

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Anticancer Drugs Market

4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Anticancer Drugs Market Analysis and Forecast, 2023–2031

5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Anticancer Drugs Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Type, 2023–2031
6.3.1. Cytotoxic Drugs
6.3.1.1. Alkylating Agents
6.3.1.2. Antimetabolites
6.3.1.3. Others
6.3.2. Targeted Drugs
6.3.2.1. Monoclonal Antibodies
6.3.2.2. Tyrosine Kinase Inhibitors
6.3.2.3. Others
6.3.3. Hormonal Drugs
6.4. Market Attractiveness Analysis, by Drug Type

7. Global Anticancer Drugs Market Analysis and Forecast, by Therapy Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Therapy Type, 2023–2031
7.3.1. Chemotherapy
7.3.2. Targeted Therapy
7.3.3. Immunotherapy
7.3.4. Others
7.4. Market Attractiveness Analysis, by Therapy Type

8. Global Anticancer Drugs Market Analysis and Forecast, by Cancer Type
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Cancer Type, 2023–2031
8.3.1. Lung Cancer
8.3.2. Breast Cancer
8.3.3. Leukemia
8.3.4. Colorectal Cancer
8.3.5. Others
8.4. Market Attractiveness Analysis, by Therapy Type

9. Global Anticancer Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2023–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region

10. North America Anticancer Drugs Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Type, 2023–2031
10.3.1. Cytotoxic Drugs
10.3.1.1. Alkylating Agents
10.3.1.2. Antimetabolites
10.3.1.3. Others
10.3.2. Targeted Drugs
10.3.2.1. Monoclonal Antibodies
10.3.2.2. Tyrosine Kinase Inhibitors
10.3.2.3. Others
10.3.3. Hormonal Drugs
10.4. Market Value Forecast, by Therapy Type, 2023–2031
10.4.1. Chemotherapy
10.4.2. Targeted Therapy
10.4.3. Immunotherapy
10.4.4. Others
10.5. Market Value Forecast, by Cancer Type, 2023–2031
10.5.1. Lung Cancer
10.5.2. Breast Cancer
10.5.3. Leukemia
10.5.4. Colorectal Cancer
10.5.5. Others
10.6. Market Value Forecast, by Country, 2023–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Drug Type
10.7.2. By Therapy Type
10.7.3. By Cancer Type
10.7.4. By Country

11. Europe Anticancer Drugs Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Type, 2023–2031
11.3.1. Cytotoxic Drugs
11.3.1.1. Alkylating Agents
11.3.1.2. Antimetabolites
11.3.1.3. Others
11.3.2. Targeted Drugs
11.3.2.1. Monoclonal Antibodies
11.3.2.2. Tyrosine Kinase Inhibitors
11.3.2.3. Others
11.3.3. Hormonal Drugs
11.4. Market Value Forecast, by Therapy Type, 2023–2031
11.4.1. Chemotherapy
11.4.2. Targeted Therapy
11.4.3. Immunotherapy
11.4.4. Others
11.5. Market Value Forecast, by Cancer Type, 2023–2031
11.5.1. Lung Cancer
11.5.2. Breast Cancer
11.5.3. Leukemia
11.5.4. Colorectal Cancer
11.5.5. Others
11.6. Market Value Forecast, by Country/Sub-region, 2023–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Drug Type
11.7.2. By Therapy Type
11.7.3. By Cancer Type
11.7.4. By Country/Sub-region

12. Asia Pacific Anticancer Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Type, 2023–2031
12.3.1. Cytotoxic Drugs
12.3.1.1. Alkylating Agents
12.3.1.2. Antimetabolites
12.3.1.3. Others
12.3.2. Targeted Drugs
12.3.2.1. Monoclonal Antibodies
12.3.2.2. Tyrosine Kinase Inhibitors
12.3.2.3. Others
12.3.3. Hormonal Drugs
12.4. Market Value Forecast, by Therapy Type, 2023–2031
12.4.1. Chemotherapy
12.4.2. Targeted Therapy
12.4.3. Immunotherapy
12.4.4. Others
12.5. Market Value Forecast, by Cancer Type, 2023–2031
12.5.1. Lung Cancer
12.5.2. Breast Cancer
12.5.3. Leukemia
12.5.4. Colorectal Cancer
12.5.5. Others
12.6. Market Value Forecast, by Country/Sub-region, 2023–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Drug Type
12.7.2. By Therapy Type
12.7.3. By Cancer Type
12.7.4. By Country/Sub-region

13. Latin America Anticancer Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Type, 2023–2031
13.3.1. Cytotoxic Drugs
13.3.1.1. Alkylating Agents
13.3.1.2. Antimetabolites
13.3.1.3. Others
13.3.2. Targeted Drugs
13.3.2.1. Monoclonal Antibodies
13.3.2.2. Tyrosine Kinase Inhibitors
13.3.2.3. Others
13.3.3. Hormonal Drugs
13.4. Market Value Forecast, by Therapy Type, 2023–2031
13.4.1. Chemotherapy
13.4.2. Targeted Therapy
13.4.3. Immunotherapy
13.4.4. Others
13.5. Market Value Forecast, by Cancer Type, 2023–2031
13.5.1. Lung Cancer
13.5.2. Breast Cancer
13.5.3. Leukemia
13.5.4. Colorectal Cancer
13.5.5. Others
13.6. Market Value Forecast, by Country/Sub-region, 2023–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Drug Type
13.7.2. By Therapy Type
13.7.3. By Cancer Type
13.7.4. By Country/Sub-region

14. Middle East & Africa Anticancer Drugs Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Type, 2023–2031
14.3.1. Cytotoxic Drugs
14.3.1.1. Alkylating Agents
14.3.1.2. Antimetabolites
14.3.1.3. Others
14.3.2. Targeted Drugs
14.3.2.1. Monoclonal Antibodies
14.3.2.2. Tyrosine Kinase Inhibitors
14.3.2.3. Others
14.3.3. Hormonal Drugs
14.4. Market Value Forecast, by Therapy Type, 2023–2031
14.4.1. Chemotherapy
14.4.2. Targeted Therapy
14.4.3. Immunotherapy
14.4.4. Others
14.5. Market Value Forecast, by Cancer Type, 2023–2031
14.5.1. Lung Cancer
14.5.2. Breast Cancer
14.5.3. Leukemia
14.5.4. Colorectal Cancer
14.5.5. Others
14.6. Market Value Forecast, by Country/Sub-region, 2023–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Drug Type
14.7.2. By Therapy Type
14.7.3. By Cancer Type
14.7.4. By Country/Sub-region

15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. F. Hoffmann-La Roche Ltd
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Eli Lilly and Company
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Novartis AG
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Pfizer Inc
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Bayer AG
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. AstraZeneca
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Takeda Pharmaceutical Company Limited
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Merck & Co., Inc
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. CELGENE CORPORATION
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Amgen Inc
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview

List of Tables

Table 01: Global Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023–2031

Table 02: Global Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023–2031

Table 03: Global Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023–2031

Table 04: Global Anticancer Drugs Market Size (US$ Mn) Forecast, by Region, 2023–2031

Table 05: North America Anticancer Drugs Market Size (US$ Mn) Forecast, by Country, 2023–2031

Table 06: North America Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023–2031

Table 07: North America Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023–2031

Table 08: North America Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023–2031

Table 09: Europe Anticancer Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

Table 10: Europe Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023–2031

Table 11: Europe Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023–2031

Table 12: Europe Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023–2031

Table 13: Asia Pacific Anticancer Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

Table 14: Asia Pacific Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023–2031

Table 15: Asia Pacific Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023–2031

Table 16: Asia Pacific Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023–2031

Table 17: Latin America Anticancer Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

Table 18: Latin America Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023–2031

Table 19: Latin America Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023–2031

Table 20: Latin America Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023–2031

Table 21: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

Table 22: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2023–2031

Table 23: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2023–2031

Table 24: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast, by Cancer Type, 2023–2031

List of Figures

Figure 01: Global Anticancer Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2031

Figure 02: Global Anticancer Drugs Market Revenue (US$ Mn), by Drug Type, 2022

Figure 03: Global Anticancer Drugs Market Value Share, by Drug Type, 2022

Figure 04: Global Anticancer Drugs Market Revenue (US$ Mn), by Therapy Type, 2022

Figure 05: Global Anticancer Drugs Market Value Share, by Therapy Type, 2022

Figure 06: Global Anticancer Drugs Market Revenue (US$ Mn), by Cancer Type, 2022

Figure 07: Global Anticancer Drugs Market Value Share, by Cancer Type, 2022

Figure 08: Global Anticancer Drugs Market Value Share, by Region, 2022

Figure 09: Global Anticancer Drugs Market Value (US$ Mn) Forecast, 2023–2031

Figure 10: Global Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031

Figure 11: Global Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031

Figure 12: Global Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031

Figure 13: Global Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023-2031

Figure 14: Global Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031

Figure 15: Global Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023-2031

Figure 16: Global Anticancer Drugs Market Value Share Analysis, by Region, 2023 and 2031

Figure 17: Global Anticancer Drugs Market Attractiveness Analysis, by Region, 2023-2031

Figure 18: North America Anticancer Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031

Figure 19: North America Anticancer Drugs Market Attractiveness Analysis, by Country, 2023–2031

Figure 20: North America Anticancer Drugs Market Value Share Analysis, by Country, 2023 and 2031

Figure 21: North America Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031

Figure 22: North America Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031

Figure 23: North America Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031

Figure 24: North America Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031

Figure 25: North America Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023–2031

Figure 26:North America Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023–2031

Figure 27: Europe Anticancer Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031

Figure 28: Europe Anticancer Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 29: Europe Anticancer Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2031

Figure 30: Europe Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031

Figure 31: Europe Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031

Figure 32: Europe Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031

Figure 33: Europe Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031

Figure 34: Europe Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023–2031

Figure 35: Europe Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023–2031

Figure 36: Asia Pacific Anticancer Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031

Figure 37: Asia Pacific Anticancer Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 38: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2031

Figure 39: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031

Figure 40: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031

Figure 41: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031

Figure 42: Asia Pacific Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031

Figure 43: Asia Pacific Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023–2031

Figure 44: Asia Pacific Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023–2031

Figure 45: Latin America Anticancer Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031

Figure 46: Latin America Anticancer Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 47: Latin America Anticancer Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2031

Figure 48: Latin America Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031

Figure 49: Latin America Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031

Figure 50: Latin America Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031

Figure 51: Latin America Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031

Figure 52: Latin America Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023–2031

Figure 53: Latin America Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023–2031

Figure 54: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031

Figure 55: Middle East & Africa Anticancer Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 56: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2031

Figure 57: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Drug Type, 2023 and 2031

Figure 58: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2023 and 2031

Figure 59: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2023 and 2031

Figure 60: Middle East & Africa Anticancer Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031

Figure 61: Middle East & Africa Anticancer Drugs Market Attractiveness Analysis, by Therapy Type, 2023–2031

Figure 62: Middle East & Africa Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2023–2031

△ 一番上に戻る